Impact of Renin‐Angiotensin System Inhibitors on Long‐Term Clinical Outcomes of Patients With Coronary Artery Spasm
Key result
Chronic RAS inhibitor therapy was associated with a lower 5-year incidence of major adverse cardiovascular events compared to no RAS inhibitors (1.0% vs 4.1%, P=0.026).
Why the study?
Does RAS inhibitor therapy reduce cardiovascular events in patients with coronary artery spasm?
Population
3,349 patients with no significant coronary artery disease, diagnosed with coronary artery spasm by…
Comparison
Renin-angiotensin system (RAS) inhibitor therapy vs No RAS inhibitor therapy
Design
Cohort
Follow-up
5 years
Authors
Discussion
Loading...
Member takes
Implication
Supports RAS inhibitor association with fewer events in spasm; hypothesis-generating, needs RCTs before practice change.
Study Design
Type
Cohort (n=3,349)
Structured PICO
Does RAS inhibitor therapy reduce cardiovascular events in patients with coronary artery spasm?
P
Population
3,349 patients with no significant coronary artery disease diagnosed with coronary artery spasm by acetylcholine provocation test, followed for 5 years.
E
Exposure
Renin-angiotensin system (RAS) inhibitor therapy
C
Comparator
No RAS inhibitor therapy (propensity score matched)
O
Outcome
Incidence of recurrent angina, total death, and total major adverse cardiovascular eventshard clinical
Main Result
Absolute Event Rate: 1% vs 4.1%
p-value: p=0.026
Chronic RAS inhibitor therapy is associated with a lower incidence of long-term cardiovascular events and recurrent angina in patients with coronary artery spasm.
Cite This Study
Choi et al. (2016) conducted a cohort in Coronary artery spasm (n=3,349). Renin-angiotensin system (RAS) inhibitors vs. No RAS inhibitor was evaluated on Total major adverse cardiovascular events (p=0.026). Chronic RAS inhibitor therapy was associated with a lower 5-year incidence of major adverse cardiovascular events compared to no RAS inhibitors (1.0% vs 4.1%, P=0.026).